Aukrust P, Müller F, Frøland S S
Research Institute for Internal Medicine, Medical Department A, University of Oslo, Rikshospitalet, Norway.
J Infect Dis. 1998 Apr;177(4):1091-6. doi: 10.1086/517402.
RANTES has been found to suppress human immunodeficiency virus type 1 (HIV-1) replication. To further elucidate the role of this chemokine in HIV-1 infection, RANTES levels were analyzed in serum and platelet-free plasma (PFP) in 53 HIV-1-infected patients and 20 controls. RANTES levels were significantly elevated in both serum and PFP in all clinical stages of HIV-1 infection, with the highest levels in CDC groups A and B. In longitudinal testing, the progressors were characterized by a pronounced decline in serum levels over time; the nonprogressors, however, had only a slight reduction or an increase in RANTES levels. During 16 weeks of indinavir therapy, there was an increase in circulating RANTES levels and enhanced release of RANTES from stimulated CD8+ lymphocytes. The decline in RANTES levels along with disease progression is compatible with RANTES having a beneficial role in HIV-1-infected patients. The increase in RANTES levels during protease inhibitor-containing regimens may represent a previously unrecognized immunologic effect of such therapy.
已发现调节激活正常T细胞表达和分泌的趋化因子（RANTES）可抑制1型人类免疫缺陷病毒（HIV-1）复制。为进一步阐明这种趋化因子在HIV-1感染中的作用，对53例HIV-1感染患者和20名对照者的血清及无血小板血浆（PFP）中的RANTES水平进行了分析。在HIV-1感染的所有临床阶段，血清和PFP中的RANTES水平均显著升高，在疾病控制中心（CDC）A组和B组中水平最高。在纵向检测中，疾病进展者的特征是血清水平随时间显著下降；然而，疾病非进展者的RANTES水平仅有轻微降低或升高。在茚地那韦治疗的16周期间，循环RANTES水平升高，且刺激的CD8 +淋巴细胞释放RANTES增加。RANTES水平随疾病进展而下降，这与RANTES在HIV-1感染患者中发挥有益作用相一致。含蛋白酶抑制剂方案治疗期间RANTES水平升高可能代表了此类治疗之前未被认识到的免疫效应。
